LianBio
(OTC: LIANY)
|
4:59 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $0.30 | Change: +0.00 | %Change: +1.30% | Volume: 37,466 |
Open: | $ 0.30 | Volume: | 37,466 | |
---|---|---|---|---|
High: | $ 0.32 | Yield(%) | 0.00 | |
Low: | $ 0.30 | P/E Ratio (ttm): | 0.10 | |
Dividend ($): | 4.75 | Market Cap ($): | 32.61M | |
EPS ($) | 2.91 | Shares Out: | 108.71M |
% Price Change (last 4 weeks): | -11.13 |
---|---|
% Price Change (last 13 weeks): | -5.61 |
% Price Change (last 26 weeks): | -93.11 |
% Price Change (last 52 weeks): | -86.97 |
% Price Change (year to date): | -93.29 |
Return on Equity (%): | 73.99 |
---|---|
Return on Assets (%): | 66.35 |
Return on Invested Capital (%): | -34.65 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $0.31 |
---|---|
200-day Moving Average: | $2.42 |
Avg. Daily Vol. (last 50 days): | 89,234 |
Avg. Daily Vol. (last 200 days): | 1,121,802 |
52-wk high: | $4.99 |
52-wk low: | $0.24 |
Bid: | $n/a |
Ask: | $n/a |
LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. It develops a portfolio of clinically validated product candidates for cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. The company was founded by Konstantin Poukalov on July 17, 2019 and is headquartered in Princeton, NJ.
|
LianBio
103 Carnegie Center Drive Suite 309 Princeton NJ 08540 Phone: 1.609.486.2308 Fax: n/a http://www.lianbio.com |
Earnings (1year) ($): | 2.91 |
---|---|
Annual Dividend ($): | n/a |
Current P/E Ratio (ttm): | 0.10 |
Book Value ($): | 5.35 |
Cash Flow ($): | 2.87 |
Price/Earnings (x): | 0.10 |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 0.84 |
Price/Cash Flow (x): | 1.87 |
Quick Ratio (x): | 17.03 |
---|---|
Current Ratio (x): | 17.03 |
LT Debt/Equity (x): | 0.09 |
Total Debt/Equity (x): | 0.42 |